MannKind Corporation (NASDAQ:MNKD) could be ready to capture an enticing amount of diabetes market share despite what the Street mostly dismissed as a third quarter stumble for its inhalable insulin Afrezza. What has H.C. Wainwright’s Oren Livnat so confident that more script growth lies ahead for the biotech firm?
Story Continues
